Azusa, California
United States
71
2026-05-14
The entities that hold a legal rights for patent applications filed by inventor Moore Gregory:
Gregory Moore from Azusa, US has applied for patents for these inventions. The list has both pending applications and granted patents:
BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28
#2 | 2025-12-25ANTI-CD28 X ANTI-PSMA ANTIBODIES
#3 | 2025-10-30BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
#4 | 2025-10-02HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#5 | 2025-05-15ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
#6 | 2025-04-03HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#7 | 2025-04-03HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38
#8 | 2025-03-13ANTI-CD28 X ANTI-ENPP3 ANTIBODIES
#9 | 2025-03-13ANTI-CD28 X ANTI-TROP2 ANTIBODIES
#10 | 2025-02-06ANTI-CD28 COMPOSITIONS
#11 | 2024-11-28B-CELL MATURATION ANTIGEN (BCMA) BINDING DOMAIN COMPOSITIONS
#12 | 2024-10-31ORTHOGONAL MULTIMERIC PROTEINS
#13 | 2024-09-12ANTI-STEAP1 ANTIGEN-BINDING PROTEIN
#14 | 2024-07-25HETERODIMERIC ANTIBODIES THAT BIND CLAUDIN18.2 AND CD3
#15 | 2024-07-04ANTI-CD28 X ANTI-PSMA ANTIBODIES
#16 | 2024-05-23IL18-FC FUSION PROTEINS
#17 | 2024-03-21HETERODIMERIC PROTEINS
#18 | 2024-02-22ANTI-CD28 X ANTI-TROP2 ANTIBODIES
#19 | 2024-01-25BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
#20 | 2023-11-30ANTIBODIES THAT BIND PD-L1, PD-L2, AND/OR CD28
#21 | 2023-11-16HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
#22 | 2023-10-26ANTI-CD28 X ANTI-MSLN ANTIBODIES
#23 | 2023-10-26TARGETED HETERODIMERIC FC FUSION PROTEINS CONTAINING IL-15/IL-15RA AND NKG2D ANTIGEN BINDING DOMAINS
#24 | 2023-10-12ANTI-CD28 X ANTI-PSMA ANTIBODIES
#25 | 2023-08-24ANTI-CD28 X ANTI-PSMA ANTIBODIES
#26 | 2023-08-17ANTI-CD28 COMPOSITIONS
#27 | 2023-07-20HETERODIMERIC ANTIBODIES THAT BIND ENPP3 AND CD3
#28 | 2023-05-11IL-18-FC FUSION PROTEINS
#29 | 2023-03-23TRISPECIFIC ANTIBODIES
#30 | 2023-02-09BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIES
#31 | 2022-12-22Heterodimeric antibodies that bind CD3 and CD38
#32 | 2022-07-21ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
#33 | 2022-06-30Bispecific and monospecific antibodies using novel anti-PD-1 sequences
#34 | 2022-05-26Heterodimeric antibodies that bind CD3 and tumor antigens
#35 | 2022-05-26Heterodimeric antibodies that bind somatostatin receptor 2
#36 | 2022-05-12HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII
#37 | 2022-05-05BISPECIFIC ANTIBODIES THAT BIND PD-L1 AND CD28
#38 | 2022-04-21Anti-CD28 compositions
#39 | 2022-03-31Anti-CD28 compositions
#40 | 2022-02-10Heterodimeric antibodies that bind CD3 and tumor antigens
#41 | 2021-08-19BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
#42 | 2021-06-17Anti-STEAP1 antigen-binding protein
#43 | 2021-06-10Heterodimeric proteins
#44 | 2021-06-10Untargeted and targeted IL-10 Fc-fusion proteins
#45 | 2021-04-08Heterodimeric antibodies that bind CD3 and tumor antigens
#46 | 2021-04-01BISPECIFIC IMMUNOMODULATORY ANTIBODIES THAT BIND COSTIMULATORY AND CHECKPOINT RECEPTORS
#47 | 2020-10-08Heterodimeric antibodies that bind ENPP3 and CD3
#48 | 2020-08-06Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
#49 | 2020-06-25Heterodimeric antibodies that bind CD3 and CD38
#50 | 2020-04-23Heterodimeric Fc variants
#51 | 2019-12-26Bispecific checkpoint inhibitor antibodies
#52 | 2019-12-19Bispecific checkpoint inhibitor antibodies
#53 | 2019-11-21TRISPECIFIC ANTIBODIES
#54 | 2019-09-05Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
#55 | 2019-08-29Bispecific and monospecific antibodies using novel anti-PD-1 sequences
#56 | 2019-08-15Heterodimeric antibodies that bind somatostatin receptor 2
#57 | 2019-07-04Heterodimeric antibodies that bind CD3 and tumor antigens
#58 | 2018-10-04Heterodimeric antibodies that bind CD3 and tumor antigens
#59 | 2018-08-09Heterodimeric antibodies that bind CD3 and tumor antigens
#60 | 2018-08-02Heterodimeric proteins
#61 | 2018-05-10Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
#62 | 2018-05-03Bispecific checkpoint inhibitor antibodies
#63 | 2018-05-03Heterodimeric antibodies that bind somatostatin receptor 2
#64 | 2017-03-23Heterodimeric antibodies to CD3 X CD123
#65 | 2017-03-23Heterodimeric antibodies to CD3 X CD20
#66 | 2017-03-02COMPOSITIONS AND METHODS FOR SIMULTANEOUS BIVALENT AND MONOVALENT CO-ENGAGEMENT OF ANTIGENS
#67 | 2016-12-08Heterodimeric antibodies that bind CD3 and tumor antigens
#68 | 2016-12-08Trispecific antibodies
#69 | 2016-08-11Heterodimeric antibodies that bind CD3 and tumor antigens
#70 | 2016-07-28Heterodimeric antibodies that bind CD3 and CD38
#71 | 2016-06-23HETERODIMERIC ANTIBODIES INCLUDING BINDING TO CD8
1568950 ⎘